Ginkgo Bioworks Holdings Q2 EPS $(0.09), Inline, Sales $80.57M Beat $71.58M Estimate
Portfolio Pulse from totan@benzinga.com
Ginkgo Bioworks Holdings (NYSE:DNA) reported Q2 earnings per share (EPS) of $(0.09), in line with analyst consensus. This is a 78.05% increase over losses from the same period last year. The company's quarterly sales of $80.57M beat the analyst consensus estimate of $71.58M by 12.56%, but this is a 44.29% decrease over sales of $144.62M the same period last year.
August 09, 2023 | 9:16 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ginkgo Bioworks' Q2 EPS met analyst expectations, and sales beat estimates but were down YoY. This mixed report may lead to uncertain short-term price movement.
Ginkgo Bioworks' Q2 earnings were in line with analyst expectations, and sales beat estimates, which could be seen as positive. However, the YoY decrease in sales could be a concern for investors, leading to uncertainty in the short-term price movement.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100